PD Strat V1

  • Research type

    Research Study

  • Full title

    Patient stratification, mitochondrial dysfunction and gait in Parkinson's Disease

  • IRAS ID

    371307

  • Contact name

    Oliver Bandmann

  • Contact email

    o.bandmann@sheffield.ac.uk

  • Sponsor organisation

    Sheffield Teaching hospitals

  • Duration of Study in the UK

    5 years, 2 months, 1 days

  • Research summary

    Parkinson’s disease (PD) patients present in many different ways. Two common patterns are those that are predominantly affected by tremor, ‘Tremor-Dominant-PD’(TD-PD) and those that are more affected by balance and walking issues, ‘Postural instability and gait difficulty-PD’(PIGD-PD). PIGD-PD presentations are linked with faster progression to disability and memory problems.

    There is growing evidence that dysfunction of mitochondria (“powerhouses” of cells that produce energy) contributes to the cause of PD. A recent post-mortem study suggested that PD patients with more severe and widespread mitochondrial dysfunction in the brain predominantly had PIGD-PD presentations. This indicates that patients with PIGD-PD are more likely to respond to medications targeting mitochondrial function.

    Current tools to differentiate TD-PD and PIGD-PD are based on clinical rating scales which can vary between assessors. Therefore, validated objective tools to differentiate subgroups would be superior.

    Outcome measures from wearable sensors (WS) can differentiate healthy volunteers from PD patients and show differences between PIGD-PD and TD-PD subgroups. Therefore, we suggest WS can aid stratification into these subgroups.

    We will recruit 50 people diagnosed with PD in the last 3 years and 20 age-matched healthy volunteers. Participants will undergo detailed clinical assessment, along with walking and tremor assessments using WS in supervised and real-world settings. Additionally, blood tests and specialised MRI scans will be acquired to investigate markers of mitochondrial health.

    We will use WS Digital outcomes to create an objective score reflecting whether patients have TD-PD or PIGD-PD. We will then compare markers of mitochondrial health between the two groups.

    Participants will be invited back after two years to repeat all assessments to allow assessment of disease progression and to see if patients remain in the same subgroup.
    We hypothesise that patients stratified into the PIGD-PD subgroup will show evidence of greater mitochondrial dysfunction and will progress at a faster rate.

  • REC name

    West Midlands - Black Country Research Ethics Committee

  • REC reference

    26/WM/0134

  • Date of REC Opinion

    7 Aug 2026

  • REC opinion

    Further Information Favourable Opinion